Pro Selling And Marketing Expenses vs Income Tax Expense Analysis
PME Stock | 251.89 3.71 1.49% |
Pro Medicus financial indicator trend analysis is much more than just breaking down Pro Medicus prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Pro Medicus is a good investment. Please check the relationship between Pro Medicus Selling And Marketing Expenses and its Income Tax Expense accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pro Medicus. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Selling And Marketing Expenses vs Income Tax Expense
Selling And Marketing Expenses vs Income Tax Expense Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Pro Medicus Selling And Marketing Expenses account and Income Tax Expense. At this time, the significance of the direction appears to have almost identical trend.
The correlation between Pro Medicus' Selling And Marketing Expenses and Income Tax Expense is 0.91. Overlapping area represents the amount of variation of Selling And Marketing Expenses that can explain the historical movement of Income Tax Expense in the same time period over historical financial statements of Pro Medicus, assuming nothing else is changed. The correlation between historical values of Pro Medicus' Selling And Marketing Expenses and Income Tax Expense is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Selling And Marketing Expenses of Pro Medicus are associated (or correlated) with its Income Tax Expense. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Income Tax Expense has no effect on the direction of Selling And Marketing Expenses i.e., Pro Medicus' Selling And Marketing Expenses and Income Tax Expense go up and down completely randomly.
Correlation Coefficient | 0.91 |
Relationship Direction | Positive |
Relationship Strength | Very Strong |
Selling And Marketing Expenses
Income Tax Expense
Most indicators from Pro Medicus' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Pro Medicus current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pro Medicus. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. Selling General Administrative is likely to gain to about 31.9 M in 2024. Tax Provision is likely to gain to about 35.4 M in 2024
2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 7.9M | 8.5M | 10.1M | 9.6M | EBITDA | 70.4M | 94.1M | 120.8M | 126.8M |
Pro Medicus fundamental ratios Correlations
Click cells to compare fundamentals
Pro Medicus Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Pro Medicus fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 95.6M | 125.6M | 157.1M | 202.1M | 257.4M | 270.3M | |
Short Long Term Debt Total | 2.3M | 2.6M | 2.3M | 1.9M | 2.1M | 1.8M | |
Other Current Liab | 4.1M | 5.6M | 8.2M | 10.0M | 12.8M | 13.5M | |
Total Current Liabilities | 12.7M | 17.6M | 26.9M | 30.9M | 34.6M | 36.3M | |
Total Stockholder Equity | 60.2M | 81.7M | 101.7M | 138.8M | 187.7M | 197.1M | |
Property Plant And Equipment Net | 2.8M | 3.0M | 2.6M | 2.2M | 2.4M | 3.0M | |
Current Deferred Revenue | 7.2M | 8.9M | 10.1M | 12.6M | 17.1M | 17.9M | |
Net Debt | (41.1M) | (39.4M) | (61.4M) | (89.4M) | (58.0M) | (55.1M) | |
Retained Earnings | 49.6M | 66.9M | 92.6M | 127.1M | 173.4M | 182.0M | |
Accounts Payable | 835K | 872K | 1.6M | 1.0M | 1.7M | 1.8M | |
Cash | 43.4M | 42.0M | 63.7M | 91.2M | 60.1M | 63.1M | |
Non Current Assets Total | 34.2M | 38.0M | 37.2M | 38.3M | 50.9M | 53.4M | |
Cash And Short Term Investments | 43.4M | 61.8M | 90.6M | 121.5M | 155.4M | 163.2M | |
Net Receivables | 17.0M | 24.4M | 27.4M | 40.7M | 49.2M | 51.7M | |
Common Stock Shares Outstanding | 104.5M | 104.6M | 104.6M | 104.6M | 104.7M | 111.9M | |
Liabilities And Stockholders Equity | 95.6M | 125.6M | 157.1M | 202.1M | 257.4M | 270.3M | |
Non Current Liabilities Total | 22.7M | 26.3M | 28.5M | 32.5M | 35.1M | 36.9M | |
Inventory | 35K | 34K | 77K | 55K | 49K | 75.3K | |
Other Stockholder Equity | (51.6M) | (68.9M) | (94.5M) | (129.1M) | (116.2M) | (110.4M) | |
Total Liab | 35.5M | 43.9M | 55.3M | 63.4M | 69.7M | 73.2M | |
Property Plant And Equipment Gross | 2.8M | 6.9M | 6.3M | 6.3M | 2.4M | 2.3M | |
Total Current Assets | 61.5M | 87.6M | 119.8M | 163.8M | 206.6M | 216.9M | |
Accumulated Other Comprehensive Income | 8.6M | 12.8M | 7.2M | 9.7M | (9.3M) | (8.8M) | |
Short Term Debt | 522K | 574K | 604K | 1.4M | 553K | 525.4K | |
Other Liab | 21.0M | 24.2M | 26.8M | 31.3M | 36.0M | 37.8M | |
Other Assets | 9.4M | 13.2M | 40.5M | 1.0 | 12.4M | 0.95 | |
Other Current Assets | 1.0M | 1.3M | 1.8M | 1.6M | 1.9M | 950.4K | |
Property Plant Equipment | 2.8M | 3.0M | 2.6M | 2.2M | 2.5M | 2.6M | |
Non Currrent Assets Other | 237K | 30.0K | (1.0) | 242K | 40K | 42K | |
Intangible Assets | 18.8M | 20.0M | 22.3M | 21.3M | 20.1M | 10.2M | |
Net Tangible Assets | 41.3M | 61.7M | 79.4M | 117.4M | 135.0M | 141.8M | |
Long Term Debt Total | 1.8M | 2.0M | 1.7M | 1.2M | 1.4M | 1.0M | |
Net Invested Capital | 60.2M | 81.7M | 101.7M | 138.8M | 187.7M | 96.2M | |
Net Working Capital | 48.8M | 69.9M | 93.0M | 132.9M | 172.0M | 180.6M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Pro Stock Analysis
When running Pro Medicus' price analysis, check to measure Pro Medicus' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pro Medicus is operating at the current time. Most of Pro Medicus' value examination focuses on studying past and present price action to predict the probability of Pro Medicus' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pro Medicus' price. Additionally, you may evaluate how the addition of Pro Medicus to your portfolios can decrease your overall portfolio volatility.